| HOME >> MEDICINE >> TECHNOLOGY |
AIDS/HIV 57
Nucleoside Reverse Transcriptase Inhibitor (NRTI) 58
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) 58
Protease Inhibitors 58
TABLE 23 MARKET FOR LEADING PRODUCTS: VIRAL INFECTION
DISEASE, THROUGH 2010 ($ MILLIONS) 59
VACCINES 59
TABLE 24 MARKET BY DRUG CLASS FOR VACCINES, THROUGH
2010 ($ MILLIONS) 59
Hepatitis 60
Hepatitis A and E 60
Hepatitis B 60
Hepatitis C 60
Hepatitis C (Continued) 61
Hepatitis D (with B) 62
Hepatitis G 62
Interferons 62
Antivirals 62
TABLE 25 MARKET FOR LEADING PRODUCTS: VACCINETREATABLE
DISEASE, THROUGH 2010 ($ MILLIONS) 63
FUNGAL INFECTIONS 63
TABLE 26 MARKET BY DRUG CLASS FOR FUNGAL INFECTIONS,
THROUGH 2010 ($ MILLIONS) 63
Fungal Infections (Continued) 64
TABLE 27 MARKET FOR LEADING PRODUCTS: FUNGAL DISEASE,
THROUGH 2010 ($ MILLIONS) 65
TRENDS AND INNOVATIONS IN INFECTIOUS DISEASE 65
KEY TRENDS IN INFECTIOUS DISEASE 65
Large and Growing Opportunity: Drug Resistant
Infections 66
Emerging Markets Open HIV/AIDS Drugs to Fast
Growth 66
Hepatitis C as Major Need Matched with Novel
Last-Stage Compounds 66
Novel Vaccines Drive Future Sales Growth 66
Flu Pandemics Offer Latent Opportunity 67
MARKET FORECAST 67
TABLE 28 MARKET FORECAST FOR INFECTIOUS DISEASE,
THROUGH 2015 ($ MILLIONS) 68
PIPELINE ANALYSIS 68
TABLE 29 PRODUCTS IN DEVELOPMENT BY STAGE AND
INFECTIOUS DISEASE SEGMENT (NUMBER OF
DEVELOPMENTAL PRODUCTS) 69
PROFILES OF KEY PRODUCTS IN DEVELOPMENT 69
RECENTLY APPROVED DRUGS 69
Doribax 69
TABLE 30 PRODUCT PROFILE SUMMARY: DORIBAX 69
Isentress 70
TABLE 31 PRODUCT PROFILE SUMMARY: ISENTRESS 70
Prezista 71
TABLE 32 PRODUCT PROFILE SUMMARY: PREZIST
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |